Table 1

 Baseline patient characteristics

CharacteristicMethotrexateEtanerceptCombination
(n = 228)(n = 223)(n = 231)
*n = 227 and 230 for methotrexate and combination, respectively.
DMARDs, disease modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire disability index; EQ-5D VAS, EuroQoL health status visual analogue scale; GHVAS: patient general health visual analogue scale; PGAD, patient global assessment.
Age (years), mean (SD)53.0 (12.8)53.2 (13.8)52.5 (12.4)
Women, No (%)180 (79)171 (77)171 (74)
White, No (%)224 (98)220 (99)227 (98)
Disease duration (years), mean (SD)6.8 (5.5)6.3 (5.1)6.8 (5.4)
Number of prior DMARDs, mean (SD)2.3 (1.6)2.3 (1.4)2.3 (1.4)
Prior methotrexate use, No (%)96 (42)93 (42)101 (44)
HAQ score*, mean (SD)1.7 (0.7)1.7 (0.7)1.8 (0.6)
EQ-5D VAS score, mean (SD)38.2 (20.3)42.1 (21.7)40.3 (22.4)
GHVAS (mm), mean (SD)68.0 (20.5)68.2 (19.8)69.4 (19.3)
PGAD, mean (SD)6.9 (1.7)6.9 (1.7)7.2 (1.7)
Satisfied with previous medication, No (%)7 (3.1)2 (0.9)7 (3.0)